Research Article Details
| Article ID: | A52032 |
| PMID: | 32120465 |
| Source: | Ceylon Med J |
| Title: | Association of Serum Uric acid and Gamma-glutamyltransferase with Obesity Related Metabolic Derangements in a Cohort of Children with Obesity in Sri Lanka |
| Abstract: | Introduction: Gamma-glutamyltransferase (GGT) and serum uric acid (UA) are known to be associated with cardiovascular disease in obese children Objectives: To determine the association of serum UA and GGT with components of metabolic syndrome (MetS) in a group of obese children and determine the validity of UA and GGT in predicting MetS. Methods: Cross sectional analytical study was conducted among 205, 5-15 year old obese children. After a 12- hour overnight fast, blood was drawn for glucose, lipid profile, alanine aminotransferase (ALT), aspartate aminotransferase (AST), insulin, UA and GGT. Oral glucose tolerance test (OGTT) was done with 2 hour plasma glucose. Height, weight, waist circumference, blood pressure and fat mass were measured. USS of abdomen was performed to assess hepatic steatosis. Results: Chi square test showed statistically significant associations between GGT and UA with triglyceride, insulin resistance (HOMA-IR), AST, ALT, AST/ALT ratio and fatty liver. Additionally UA showed a significant association with the OGTT. With existing cut offs (GGT >30 U/L and UA >330 μmol/L) the sensitivity and specificity of GGT in predicting MetS was 19% (95% CI, 13.63-24.37) and 88.4% (95% CI, 84.02-92.78) respectively while for UA was 28.6% (95% CI, 22.42-34.78) and 80.2% (95% CI, 74.75-85.65) respectively. A new cut off value of 19.5 U/L (sensitivity 56% and specificity 55%) for GGT and 275.5 μmol/L (sensitivity 61% and specificity 54%) for UA predicted MetS with greater accuracy. Conclusion: GGT and UA are strongly associated with metabolic derangements and these biomarkers are rather weak in predicting MetS. |
| DOI: | 10.4038/cmj.v64i4.8989 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D080 | Citrulline | Chemical drug | DB00155 | -- | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |